Oyster Raises 60 Million Dollars for Tau Degraders

Oyster Therapeutics, formerly Kesmalea, announced a $60 million Series A led by 4BIO Capital on November 10. Capital is earmarked for an oral brain-penetrant tau degrader and the SELFTAC small bifunctional-degrader platform. Financing is…




